Oxford Biomedica plc (LON:OXB)
652.00
-7.00 (-1.06%)
Mar 5, 2026, 11:30 AM GMT
Oxford Biomedica Revenue
Oxford Biomedica had revenue of 73.22M GBP in the half year ending June 30, 2025, with 70.04% growth. This brings the company's revenue in the last twelve months to 151.21M, up 55.44% year-over-year. In the year 2024, Oxford Biomedica had annual revenue of 128.80M with 43.84% growth.
Revenue (ttm)
151.21M
Revenue Growth
+55.44%
P/S Ratio
5.27
Revenue / Employee
168.02K
Employees
900
Market Cap
796.56M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 128.80M | 39.26M | 43.84% |
| Dec 31, 2023 | 89.54M | -50.45M | -36.04% |
| Dec 31, 2022 | 139.99M | -2.81M | -1.97% |
| Dec 31, 2021 | 142.80M | 55.07M | 62.77% |
| Dec 31, 2020 | 87.73M | 23.67M | 36.95% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genus | 672.00M |
| Oxford Nanopore Technologies | 223.90M |
| hVIVO | 54.47M |
| Bioventix | 13.12M |
| Scancell Holdings | 4.71M |
| PureTech Health | 4.66M |
| 4basebio | 1.78M |
| Ondine Biomedical | 1.18M |
Oxford Biomedica News
- 7 days ago - EQT backs out of takeover bid for UK's Oxford Biomedica - Reuters
- 4 weeks ago - Oxford Biomedica Signs Multi-Year Commercial Supply Deal With Bristol Myers Squibb - Nasdaq
- 7 weeks ago - UK's Oxford Biomedica confirms unsolicited bid from funds managed by EQT - Reuters
- 5 months ago - Oxford Biomedica plc (OXBDF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 7 months ago - UK's Oxford Biomedica maintains annual outlook - Reuters
- 9 months ago - OXB completes acquisition of remaining stake in US subsidiary - GlobeNewsWire
- 11 months ago - Oxford Biomedica plc (OXBDF) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Oxford Biomedica plc (OXBDF) Q2 2024 Earnings Call Transcript - Seeking Alpha